“Intellia Therapeutics has surged 41% year-to-date amid FDA clearance to resume a key Phase 3 trial for its CRISPR-based therapy targeting hereditary ATTR amyloidosis with polyneuropathy, positioning the company as a frontrunner in gene editing innovation. However, ongoing clinical risks, high cash burn rates, and competition from established treatments raise questions about its long-term viability … Read more
As the U.S. sports betting industry continues its explosive growth following widespread legalization, Sportradar Group (SRAD) emerges as a classic picks-and-shovels opportunity—supplying the essential data, odds, and technology infrastructure that powers sportsbooks and leagues. With recurring revenue streams, dominant partnerships across major U.S. sports, and consistent double-digit growth, SRAD positions investors to capture upside from … Read more
“Jim Cramer expresses optimism for Intuit, labeling it as enterprise software poised for better performance despite heavy market conditions, while the company’s stock has declined 24% year-to-date in 2026 amid AI fears and slower growth projections, yet maintains double-digit guidance for fiscal 2026 with strong segments like QuickBooks and TurboTax.” Cramer’s Perspective on Intuit’s Potential … Read more
Jefferies has launched coverage on XP Inc, a leading Brazilian financial services platform, with a Buy recommendation and a $22 price target, highlighting its innovative technology-driven approach and market expansion opportunities. The initiation reflects optimism about XP’s ability to democratize investments in Brazil amid growing demand for low-fee products. Since the coverage began, XP shares … Read more